Breaking Finance News

ProQR Therapeutics NV (NASDAQ:PRQR) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Only yesterday ProQR Therapeutics NV (NASDAQ:PRQR) traded 0.72% lower at $5.41. PRQR’s 50-day moving average is $5.45 and its two hundred day moving average is $5.05. With the last close up 8.44% relative to the 200-day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. 20,089 shares of PRQR were exchanged, up from ann average volume of 17,814.

Zacks Investment Research has downgraded ProQR Therapeutics NV(NASDAQ:PRQR) to Sell in a report released 8/20/2016.

On 6/20/2016, Chardan Capital released a statement for ProQR Therapeutics NV(NASDAQ:PRQR) upped the target price from $0.00 to $4.50. At the time, this indicated a possible downside of -0.08%.

See Graphic Below:

ProQR Therapeutics NV (NASDAQ:PRQR)

Also covering ProQR Therapeutics NV’s target price, a total of 3 equity analysts have released a ratings update on the company. The consensus target stock price is $22.67 with 0 rating the stock a strong buy, 0 rating the stock a buy, 0 firms rating the stock a hold, 0 rating the company to underperform, and lastly 0 firms rating the stock as sell.

ProQR Therapeutics NV has a one-year low of $3.48 and a 52 week high of $20.05. ProQR Therapeutics NV’s market cap is currently $0.0.

Brief Synopsis On ProQR Therapeutics NV (NASDAQ:PRQR)

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, and is an oligonucleotide.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.